Intravenous NAC Use in ACLF Patients

Launched by AGA KHAN UNIVERSITY · Oct 10, 2021

Keywords

ClinConnect Summary

Introduction:

Acute on Chronic Liver Failure (ACLF) is a relatively new entity, characterized by complications of cirrhosis and high rate of organ failures. Short term mortality at 28 days is high (\>15%). ACLF is multifactorial in its etiology and there is no consensus about the definitions between different parts of the world. The Asian Pacific Association for the Study of the Liver (APASL) consensus defines ACLF as "Acute hepatic insult manifesting as jaundice (serum bilirubin ≥ 5mg/dl and coagulopathy (INR≥1.5 or prothrombin activity \<40% complicated within 4 weeks by clinical ascites...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Criteria for inclusion will be
• • Age between 18 and 70 years
• • Establishment of ACLF grade 1-3 according to EASL- CLIFF criteria
• • Willing to provide informed consent to participate in the study (by study subject or next of kin)
• Exclusion Criteria:
• • Criteria for exclusion will be
• • History of hypersensitivity to NAC
• • Hepatocellular carcinoma
• • pregnancy
• • Advanced cardiovascular or pulmonary disease
• • Advanced primary neurological disease (such as stroke)